- Home
- ICAD vs HLVX Comparison
ICAD vs HLVX Comparison
Compare ICAD & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICAD
- HLVX
- Stock Information
- Founded
- ICAD 1984
- HLVX 2020
- Country
- ICAD United States
- HLVX United States
- Employees
- ICAD N/A
- HLVX N/A
- Industry
- ICAD Medical/Dental Instruments
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ICAD Health Care
- HLVX Health Care
- Exchange
- ICAD Nasdaq
- HLVX Nasdaq
- Market Cap
- ICAD 93.9M
- HLVX 83.7M
- IPO Year
- ICAD 1986
- HLVX 2022
- Fundamental
- Price
- ICAD $3.60
- HLVX $1.90
- Analyst Decision
- ICAD Hold
- HLVX Hold
- Analyst Count
- ICAD 1
- HLVX 5
- Target Price
- ICAD N/A
- HLVX $2.33
- AVG Volume (30 Days)
- ICAD 1.8M
- HLVX 295.3K
- Earning Date
- ICAD 05-19-2025
- HLVX 05-08-2025
- Dividend Yield
- ICAD N/A
- HLVX N/A
- EPS Growth
- ICAD N/A
- HLVX N/A
- EPS
- ICAD N/A
- HLVX N/A
- Revenue
- ICAD $19,608,000.00
- HLVX N/A
- Revenue This Year
- ICAD $2.58
- HLVX N/A
- Revenue Next Year
- ICAD $14.78
- HLVX N/A
- P/E Ratio
- ICAD N/A
- HLVX N/A
- Revenue Growth
- ICAD 13.22
- HLVX N/A
- 52 Week Low
- ICAD $1.18
- HLVX $1.34
- 52 Week High
- ICAD $3.78
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- ICAD 72.92
- HLVX 60.50
- Support Level
- ICAD $3.42
- HLVX $1.81
- Resistance Level
- ICAD $3.58
- HLVX $1.94
- Average True Range (ATR)
- ICAD 0.13
- HLVX 0.10
- MACD
- ICAD 0.03
- HLVX 0.00
- Stochastic Oscillator
- ICAD 78.08
- HLVX 79.31
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.